FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2185603669> ?p ?o ?g. }

• W2185603669 endingPage "13" @default.
• W2185603669 startingPage "309" @default.
• W2185603669 abstract "An outpatient regimen of interferon-alpha (IFN-alpha), interleukin-2 (IL-2) and 5-fluorouracil (5-FU) was previously reported to have significant activity (response rate 48.6%) in patients with advanced renal cell carcinoma (RCC). The patient group reported were generally of good performance status (PS), had undergone previous nephrectomy and would be considered of good prognosis with respect to response and survival after treatment with IL-2. The characteristics of patients with RCC referred to specialist units in the UK differ from that patient group in that many patients present with metastatic disease, are of poor PS and are considered unfit for nephrectomy. We tested the three drug regimen in a representative patient group of 55 patients who had: median PS of 1 (range 0-2); median time from diagnosis to treatment of 2.7 months (0.2-113); and median number of sites of disease 3 (1-5). 22/55 had not had prior nephrectomy and 31 were considered of poor risk, 15 moderate risk and only 9 of good risk. Treatment consisted of an 8 week cycle of IFN-alpha 6 MU/m2 day 1 weeks 1 and 4 and thrice weekly weeks 2-3 and 9 MU/m2 thrice weekly, weeks 5-8. IL-2 20 MU/m2 days 3-5, weeks 1 and 4 and 5 MU/m2 thrice weekly weeks 2-3. 5-FU 750 mg/m2 day 1 of weeks 5-8. There were no complete responses (CR), 9 (17%) partial responses (PR) and 13 patients (24%) had stable disease. Sixteen patients withdrew early from treatment and were not evaluable for response. Amongst 25 evaluable patients who had undergone nephrectomy the response rate was 32% (95% CI: 14-50%). Only 1 response was seen in patients who had not undergone nephrectomy. Survival was predicted by PS, nephrectomy, number of sites of metastasis and risk group. Most patients experienced significant toxicity of grade I/II but few grade III/IV toxicities were seen as compared to intravenous IL-2 regimens. These data are part of a large data set that has been submitted for publication in The British Journal of Urology. The regimen has been shown to have activity but this is seen predominantly in patients of good PS, with prior nephrectomy and limited sites of disease. Patients of poor risk are likely to experience significant toxicity without benefit and should be offered alternative palliative therapies." @default.
• W2185603669 created "2016-06-24" @default.
• W2185603669 creator A5002527726 @default.
• W2185603669 creator A5006242228 @default.
• W2185603669 creator A5066606548 @default.
• W2185603669 creator A5086212361 @default.
• W2185603669 date "1996-10-01" @default.
• W2185603669 modified "2023-09-23" @default.
• W2185603669 title "Cytokines in combination with chemotherapy for advanced renal carcinoma--the importance of patient selection." @default.
• W2185603669 doi "https://doi.org/10.1089/cbr.1996.11.309" @default.
• W2185603669 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10851510" @default.
• W2185603669 hasPublicationYear "1996" @default.
• W2185603669 type Work @default.
• W2185603669 sameAs 2185603669 @default.
• W2185603669 citedByCount "2" @default.
• W2185603669 crossrefType "journal-article" @default.
• W2185603669 hasAuthorship W2185603669A5002527726 @default.
• W2185603669 hasAuthorship W2185603669A5006242228 @default.
• W2185603669 hasAuthorship W2185603669A5066606548 @default.
• W2185603669 hasAuthorship W2185603669A5086212361 @default.
• W2185603669 hasConcept C126322002 @default.
• W2185603669 hasConcept C126894567 @default.
• W2185603669 hasConcept C141071460 @default.
• W2185603669 hasConcept C203014093 @default.
• W2185603669 hasConcept C2776178377 @default.
• W2185603669 hasConcept C2776694085 @default.
• W2185603669 hasConcept C2777472916 @default.
• W2185603669 hasConcept C2777546739 @default.
• W2185603669 hasConcept C2780091579 @default.
• W2185603669 hasConcept C2780227381 @default.
• W2185603669 hasConcept C2781413609 @default.
• W2185603669 hasConcept C2909179924 @default.
• W2185603669 hasConcept C71924100 @default.
• W2185603669 hasConcept C90924648 @default.
• W2185603669 hasConceptScore W2185603669C126322002 @default.
• W2185603669 hasConceptScore W2185603669C126894567 @default.
• W2185603669 hasConceptScore W2185603669C141071460 @default.
• W2185603669 hasConceptScore W2185603669C203014093 @default.
• W2185603669 hasConceptScore W2185603669C2776178377 @default.
• W2185603669 hasConceptScore W2185603669C2776694085 @default.
• W2185603669 hasConceptScore W2185603669C2777472916 @default.
• W2185603669 hasConceptScore W2185603669C2777546739 @default.
• W2185603669 hasConceptScore W2185603669C2780091579 @default.
• W2185603669 hasConceptScore W2185603669C2780227381 @default.
• W2185603669 hasConceptScore W2185603669C2781413609 @default.
• W2185603669 hasConceptScore W2185603669C2909179924 @default.
• W2185603669 hasConceptScore W2185603669C71924100 @default.
• W2185603669 hasConceptScore W2185603669C90924648 @default.
• W2185603669 hasIssue "5" @default.
• W2185603669 hasLocation W21856036691 @default.
• W2185603669 hasOpenAccess W2185603669 @default.
• W2185603669 hasPrimaryLocation W21856036691 @default.
• W2185603669 hasRelatedWork W2006060500 @default.
• W2185603669 hasRelatedWork W2032422435 @default.
• W2185603669 hasRelatedWork W2095744212 @default.
• W2185603669 hasRelatedWork W2107060891 @default.
• W2185603669 hasRelatedWork W2132625873 @default.
• W2185603669 hasRelatedWork W2187200220 @default.
• W2185603669 hasRelatedWork W2321029249 @default.
• W2185603669 hasRelatedWork W2359059759 @default.
• W2185603669 hasRelatedWork W2427851099 @default.
• W2185603669 hasRelatedWork W2472347302 @default.
• W2185603669 hasVolume "11" @default.
• W2185603669 isParatext "false" @default.
• W2185603669 isRetracted "false" @default.
• W2185603669 magId "2185603669" @default.
• W2185603669 workType "article" @default.